2024
A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy
Miao Y, Niu L, Lv X, Zhang Q, Xiao Z, Ji Z, Chen L, Liu Y, Liu N, Zhu J, Yang Y, Chen Q. A Minimalist Pathogen‐Like Sugar Nanovaccine for Enhanced Cancer Immunotherapy. Advanced Materials 2024, 36: e2410715. PMID: 39210649, DOI: 10.1002/adma.202410715.Peer-Reviewed Original ResearchCancer immunotherapyMaturation of antigen-presenting cellsVaccine carriersImmune checkpoint blockade therapyAntigen-specific immune responsesInhibition of tumor growthCheckpoint blockade therapyEnhanced cancer immunotherapyAntigen-presenting cellsVaccine delivery technologiesB16-OVABlockade therapyImmune activationTumor modelTumor growthAntigen loadNanovaccineImmune responseMeticulous screeningAntigenic peptidesImmunostimulatory characteristicsChain ratioDelivery technologiesImmunotherapyIn vivoStrategically Staged Tumor Ablation and Inflammation Suppression Using Shell‐Core Nanoparticles to Eradicate Bladder Tumors and Prevent Recurrence
Xu Y, Zhang R, Zhu J, Guo Z, Jin D, Qian L, Yang Y, Chen H. Strategically Staged Tumor Ablation and Inflammation Suppression Using Shell‐Core Nanoparticles to Eradicate Bladder Tumors and Prevent Recurrence. Advanced Functional Materials 2024, 34 DOI: 10.1002/adfm.202402078.Peer-Reviewed Original ResearchPrevent tumor recurrenceBladder tumorsTumor recurrenceTumor ablationPreventing bladder tumor recurrenceRat bladder tumor modelBladder tumor modelBladder tumor recurrenceInflammation suppressionCancer-related inflammationRelease of nitric oxideAnti-inflammatory effectsAcidic tumor environmentTumor environmentTumor modelPrevent recurrenceReduce inflammationTumorRecurrenceInflammationReactive oxygen speciesNitric oxideIn vitroAbstract NanomedicineAnti-tumorMinimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy
Niu L, Miao Y, Cao Z, Wei T, Zhu J, Li M, Bai B, Chen L, Liu N, Pan F, Zhu J, Wang C, Yang Y, Chen Q. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy. ACS Nano 2024, 18: 3349-3361. PMID: 38230639, DOI: 10.1021/acsnano.3c10174.Peer-Reviewed Original ResearchConceptsTumor-specific immune responsesBone marrow-derived dendritic cellsCancer immunotherapyDendritic cellsCancer vaccinesActivate tumor-specific immune responsesCell death protein ligand 1Mouse bone marrow-derived dendritic cellsImmune responseMarrow-derived dendritic cellsAnti-PD-L1Codelivery of antigenEffective cancer vaccinesPre-existing tumorsActivated dendritic cellsAntigen cross-presentationDC maturationCross-presentationTumor modelProphylactic efficacyNanovaccineImmune effectsImmunotherapyPeptide antigensCancer
2023
Antibacterial Fusobacterium nucleatum‐Mimicking Nanomedicine to Selectively Eliminate Tumor‐Colonized Bacteria and Enhance Immunotherapy Against Colorectal Cancer
Chen L, Zhao R, Shen J, Liu N, Zheng Z, Miao Y, Zhu J, Zhang L, Wang Y, Fang H, Zhou J, Li M, Yang Y, Liu Z, Chen Q. Antibacterial Fusobacterium nucleatum‐Mimicking Nanomedicine to Selectively Eliminate Tumor‐Colonized Bacteria and Enhance Immunotherapy Against Colorectal Cancer. Advanced Materials 2023, 35: e2306281. PMID: 37722134, DOI: 10.1002/adma.202306281.Peer-Reviewed Original ResearchConceptsImmune checkpoint blockadeF. nucleatumTumor modelTherapeutic responseResponse to immune checkpoint blockadeColorectal cancerColorectal tumorsImmunosuppressive tumor microenvironmentColorectal cancer modelAnimal tumor modelsAgainst Colorectal CancerColorectal tumor cellsICB therapyCheckpoint blockadeCancer immunotherapyTumor microenvironmentFusobacterium nucleatumMC-38Cancer modelsTumor cellsClinical evidenceTumor developmentSide effectsTumorCancer treatment